CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use

Key Points

• To evaluate the progress of CYP2C19 genotype-guided dosing for proton pump inhibitors in clinical settings.
• Assessment of current clinical trials and real-world implementation
• Identification of barriers to effective genotype-guided therapy
• Exploration of future technological integrations like AI and pharmacogenomic testing
• Increased interest in personalized treatment for acid-related disorders
• Identification of challenges such as test availability and clinician awareness
• Potential for improved individual patient outcomes with multi-gene approaches and AI support